Robert D. Hunt

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.

Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.

Journal: The Lancet. Infectious diseases

Published: December 18, 2023

Advances in the treatment and prevention of HIV: what you need to know.

Advances in the treatment and prevention of HIV: what you need to know.

Journal: British journal of hospital medicine (London, England : 2005)

Published: July 25, 2023

Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.

Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.

Journal: The New England journal of medicine

Published: September 02, 2022

Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.

Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.

Journal: The New England journal of medicine

Published: March 05, 2020

Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosis.

Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosis.

Journal: BMC medicine

Published: May 23, 2017

A comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens.

A comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens.

Journal: BMC medicine

Published: March 28, 2017

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.

Journal: The Lancet. Infectious diseases

Published: May 23, 2016

Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study.

Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study.

Journal: The Lancet. Respiratory medicine

Published: January 28, 2014

Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment.

Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment.

Journal: The Lancet. Respiratory medicine

Published: January 17, 2014

Showing 1-9 of 9

Last Updated: 09/26/2026